Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Not yet recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Squamous Cell Carcinoma of Head and Neck 23Oropharyngeal Neoplasms 8Mouth Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Melanoma 6Laryngeal Neoplasms 5Hypopharyngeal Neoplasms 5Salivary Gland Neoplasms 4Nasopharyngeal Carcinoma 4Head and Neck Neoplasms 4Carcinoma 4Stomach Neoplasms 3Ovarian Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Tongue Neoplasms 2Thyroid Carcinoma, Anaplastic 2Testicular Neoplasms 2Papillomavirus Infections 2Pancreatic Neoplasms 2Neoplasms, Unknown Primary 2Neoplasms 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

Cisplatin 127Gemcitabine 71Radiotherapy, Intensity-Modulated 61toripalimab 39Capecitabine 37Docetaxel 36Fluorouracil 35Radiotherapy 24camrelizumab 23Drug Therapy 22nimotuzumab 18spartalizumab 13pembrolizumab 13nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11tislelizumab 10Nivolumab 10Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiation 9Cetuximab 9Carboplatin 9endostar protein 8Paclitaxel 8Bevacizumab 8anlotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Taxes × Head & Neck × Clear all
NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT07136519 2025-08-22

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

Affiliated Hospital of Guangdong Medical University

Phase 2 Not yet recruiting
30 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06331845 2024-03-26

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Fujian Cancer Hospital

Phase 2 Not yet recruiting
39 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04769076 2021-02-25

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
40 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡